Previous Article
PDF
Standard view
Export citation
Share
Vol.17 No.3
May, 2023
Frequency : Bimonthly
pISSN 1976-2283
eISSN 2005-1212 
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Split Viewer
Jung Won Lee 
Correspondence to: Jung Won Lee
ORCID https://orcid.org/0000-0002-7945-1618
E-mail saludos@naver.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2022;16(3):317-318. https://doi.org/10.5009/gnl220181
Published online May 15, 2022, Published date May 15, 2022
Copyright © Gut and Liver.
Inflammatory bowel diseases (IBDs) cause chronic inflammation of the bowel through various pathophysiologic mechanisms.1,2 IBD is known to be usually intractable, with increasing complications and physical and social limitations. Among the two distinct subtypes of IBD, ulcerative colitis (UC) is a unique disease usually accompanied by irregular bowel movements, bloody diarrhea, and fear of not having immediate access to a toilet. It is also known that these characteristics of UC can cause various psychiatric problems. On the other hand, uncontrolled UC can also impair this health-related quality of life (HRQL).3 It has been proven by many studies that this disease, which mostly occurs in young patients, could severely impair daily performance and work ability. In fact, the need not only to improve disease activity in IBD patients, but also to improve overall patient quality of life has been a long-standing problem. The natural course of HRQL has been often underestimated in spite of its high incidence and the problems with impaired quality of life in patients with IBD by anxiety and depression. In particular, researchers often have disagreement in their opinions about the gradual deterioration or remission of HRQL, which is considered to be a problem at the time of evaluation or a limitation by a retrospective study design.
The MOSAIK cohort is a study on patients with moderate to severe UC. This study is first systematic prospective cohort study about UC initiated in Korea.4 Moderate to severe UC patients are often accompanied by very severe endoscopic findings, rapid progression, severe complications, and poor prognosis due to poor treatment response. The MOSAIK cohort enrolls only newly diagnosed patients aged 7 years or older, and only those diagnosed within 4 weeks of the first visit and 8 weeks of the second referral. As a result, the study successfully started with 368 patients and published 1-year follow-up data in 2021.5 One-year follow-up of 276 patients was reported. Specifically, the MOSAIK study collected the Inflammatory Bowel Disease Questionnaire (IBDQ) and the 12-Item Short Form Health Survey (SF-12) at every follow-up from baseline. The MOSAIK cohort will follow up for up to 5 years. Meanwhile, in this study, IBDQ and SF-12 used as measurement tool for HRQL demonstrated significantly increasing trends.6 The change in the total IBDQ score evaluated for 205 patients demonstrated statistically significant increase from 133.9±38.0 to 172.9±33.3 on average (p<0.001). These trends have also been confirmed in prospective studies in other countries.7 Moreover, the correlation between the partial Mayo score (p<0.001) and disease activity index such as C-reactive protein and erythrocyte sedimentation rate and inflammatory markers (p<0.005) were additionally demonstrated.6 In addition, disease extent, treatment at diagnosis, and highest treatment step were not correlated with HRQL, contrary to the authors’ initial hypothesis. These results can support the authors’ opinion that optimal disease control could improve HRQL, and several indicators including partial Mayo score and inflammatory markers demonstrated potential as possible indicators for HRQL. In this MOSAIK cohort, 276 people remained in the first-year analysis, and follow-up is planned for the next 5 years, so the future trend seems favorable.5 Meanwhile, the results of the MOSAIK cohort were better than those of other cohort studies, and it is noteworthy whether these differences will continue in future HRQL. On the other hand, due to the limitations of the method for assess HRQL used in this study, evaluation through innovative technology such as mobile applications were not used. These methodological limitations can be expected to be supplemented in future new cohort study designs. In particular, in countries where the incidence of UC is rapidly increasing, such as Korea,8 it is expected that the change in HRQL due to the addition of new biologics will show a difference compared with the results of developed countries.
No potential conflict of interest relevant to this article was reported.
Gut and Liver 2022; 16(3): 317-318
Published online May 15, 2022 https://doi.org/10.5009/gnl220181
Copyright © Gut and Liver.
Jung Won Lee
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
Correspondence to:Jung Won Lee
ORCID https://orcid.org/0000-0002-7945-1618
E-mail saludos@naver.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inflammatory bowel diseases (IBDs) cause chronic inflammation of the bowel through various pathophysiologic mechanisms.1,2 IBD is known to be usually intractable, with increasing complications and physical and social limitations. Among the two distinct subtypes of IBD, ulcerative colitis (UC) is a unique disease usually accompanied by irregular bowel movements, bloody diarrhea, and fear of not having immediate access to a toilet. It is also known that these characteristics of UC can cause various psychiatric problems. On the other hand, uncontrolled UC can also impair this health-related quality of life (HRQL).3 It has been proven by many studies that this disease, which mostly occurs in young patients, could severely impair daily performance and work ability. In fact, the need not only to improve disease activity in IBD patients, but also to improve overall patient quality of life has been a long-standing problem. The natural course of HRQL has been often underestimated in spite of its high incidence and the problems with impaired quality of life in patients with IBD by anxiety and depression. In particular, researchers often have disagreement in their opinions about the gradual deterioration or remission of HRQL, which is considered to be a problem at the time of evaluation or a limitation by a retrospective study design.
The MOSAIK cohort is a study on patients with moderate to severe UC. This study is first systematic prospective cohort study about UC initiated in Korea.4 Moderate to severe UC patients are often accompanied by very severe endoscopic findings, rapid progression, severe complications, and poor prognosis due to poor treatment response. The MOSAIK cohort enrolls only newly diagnosed patients aged 7 years or older, and only those diagnosed within 4 weeks of the first visit and 8 weeks of the second referral. As a result, the study successfully started with 368 patients and published 1-year follow-up data in 2021.5 One-year follow-up of 276 patients was reported. Specifically, the MOSAIK study collected the Inflammatory Bowel Disease Questionnaire (IBDQ) and the 12-Item Short Form Health Survey (SF-12) at every follow-up from baseline. The MOSAIK cohort will follow up for up to 5 years. Meanwhile, in this study, IBDQ and SF-12 used as measurement tool for HRQL demonstrated significantly increasing trends.6 The change in the total IBDQ score evaluated for 205 patients demonstrated statistically significant increase from 133.9±38.0 to 172.9±33.3 on average (p<0.001). These trends have also been confirmed in prospective studies in other countries.7 Moreover, the correlation between the partial Mayo score (p<0.001) and disease activity index such as C-reactive protein and erythrocyte sedimentation rate and inflammatory markers (p<0.005) were additionally demonstrated.6 In addition, disease extent, treatment at diagnosis, and highest treatment step were not correlated with HRQL, contrary to the authors’ initial hypothesis. These results can support the authors’ opinion that optimal disease control could improve HRQL, and several indicators including partial Mayo score and inflammatory markers demonstrated potential as possible indicators for HRQL. In this MOSAIK cohort, 276 people remained in the first-year analysis, and follow-up is planned for the next 5 years, so the future trend seems favorable.5 Meanwhile, the results of the MOSAIK cohort were better than those of other cohort studies, and it is noteworthy whether these differences will continue in future HRQL. On the other hand, due to the limitations of the method for assess HRQL used in this study, evaluation through innovative technology such as mobile applications were not used. These methodological limitations can be expected to be supplemented in future new cohort study designs. In particular, in countries where the incidence of UC is rapidly increasing, such as Korea,8 it is expected that the change in HRQL due to the addition of new biologics will show a difference compared with the results of developed countries.
No potential conflict of interest relevant to this article was reported.
pISSN 1976-2283
eISSN 2005-1212
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
